Stock AnalizAmgen Inc. AMGN
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 1983 · data as of November 13, 2026
Amgen Inc. (AMGN) is a healthcare company listed in the US with a market value of about $251.9B. In the twelve months to September 30, 2026 it had revenue of $38.9B and net income of $9.4B, a net margin of 24.1%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (0/5).
Key numbers: a P/E of 27.0, a price to free cash flow of 26.3, 5-year revenue growth of 8% a year, a 5-year average ROIC of 13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 26% below the current price.
Score: 2.4 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.9B | $36.8B | $33.4B | $28.2B | $26.3B | $26.0B | $25.4B | $23.4B | $23.7B | $22.8B | $23.0B |
| Net income | $9.4B | $7.7B | $4.1B | $6.7B | $6.6B | $5.9B | $7.3B | $7.8B | $8.4B | $2.0B | $7.7B |
| Free cash flow | $9.6B | $8.1B | $10.4B | $7.4B | $8.8B | $8.4B | $9.9B | $8.5B | $10.6B | $10.5B | $9.6B |
| EPS (diluted) | $17.25 | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 | $12.31 | $12.88 | $12.62 | $2.69 | $10.24 |
| Net margin | 24.1% | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | 28.6% | 33.6% | 35.4% | 8.7% | 33.6% |
| ROIC | — | 12.2% | 9.7% | 9.4% | 19.7% | 16.5% | 19.1% | 20.7% | 19.4% | 13.0% | 12.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 29 analysts is $431.81, 7% below the current price; targets range from $230.00 to $536.00; the consensus rating is “Hold”; expected EPS is $23.52 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Amgen’s P/E ratio?
About 27.0, based on the last twelve months of diluted earnings per share (forward P/E about 19.5).
Is Amgen stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 26% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Amgen pay a dividend?
Yes. The dividend yield is about 2.15%, and it has paid dividends for 10 years in our data.
Is Amgen a good stock to buy?
We do not give buy or sell advice. Amgen scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.